NEW YORK (TheStreet) -- RATINGS CHANGES

AbbVie (ABBV) - Get AbbVie, Inc. Report was downgraded at Morgan Stanley to equal-weight from overweight. Twelve-month price target is $72. Stock is already pricing in potential for Hepatitis-C and Humira, Morgan Stanley said.

Alico (ALCO) - Get Alico, Inc. Report was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: ALCO Ratings Report.

Advisory Board (ABCO) was upgraded at Stifel Nicolaus to buy from hold. Twelve-month price target is $47. Royall purchase should boost margins, Stifel Nicolaus said.

Ariad (ARIA) was downgraded at Credit Suisse to underperform from neutral. Twelve-month price target is $6. Launch metrics remain weak and any pricing benefit will likely be temporary, Credit Suisse said.

Eli Lilly (LLY) - Get Eli Lilly and Company (LLY) Report was upgraded at Morgan Stanley to overweight from underweight. Twelve-month price target is $85. Prospects for the company's pipeline are undervalued, Morgan Stanley said.

TheStreet Recommends

Macerich (MAC) - Get Macerich Company Report was downgraded at Deutsche Bank to hold from buy. Stock has run following disclosure of Simon Property Group (SPG) - Get Simon Property Group, Inc. Report stake in company and appears fairly valued at a 4.6% implied cap rate, Deutsche Bank said.

Prologis (PLD) - Get Prologis, Inc. Report was upgraded at Deutsche Bank to buy from hold. Rent growth is expected to accelerate and lower oil should have a positive impact on demand, said Deutsche Bank.

Science Applications International (SAIC) - Get Science Applications International Corp. Report was initiated with a hold rating at TheStreet Ratings. You can view the full analysis from the report here: SAIC Ratings Report.

Thompson Creek (TC) - Get TuanChe Ltd. Sponsored ADR Class A Report was downgraded at Deutsche Bank to hold from buy. Exiting moly business as prices fall, Deutsche Bank said. Twelve-month price target was cut to $1.60 from $3.75.

Toll Brothers (TOL) - Get Toll Brothers, Inc. Report was downgraded at RBC Capital to underperform from sector perform. Twelve-month price target is $30. Company has limited pricing power and will likely grow slower than its peers, RBC Capital said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes," which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.